Missouri § 208.229 Rebates on outpatient drugs — definitions.

Missouri Statutes

§ 208.229 — Rebates on outpatient drugs — definitions.

Missouri § 208.229

Title XIIPUBLIC HEALTH AND WELFARE

Ch. 208Old Age Assistance, Aid to Dependent Children and General Relief

This text of Missouri § 208.229 (Rebates on outpatient drugs — definitions.) is published on Counsel Stack Legal Research, covering Missouri primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Mo. Rev. Stat. § 208.229 (2026).

Text

1. Pharmaceutical manufacturers shall pay to the state, in accordance with 42 U.S.C. Section 1396r-8, rebates on eligible utilization of covered outpatient drugs dispensed to MO HealthNet participants under the MO HealthNet pharmacy program as follows:

(1)For single source drugs and innovator multiple source drugs, rebates shall reflect the manufacturer's best price, as defined by 42 CFR 447.505 , as updated and amended, and set forth in 42 CFR 447.509 , as updated and amended; and

(2)For single source drugs and innovator and noninnovator multiple source drugs, any additional rebates necessary to account for certain price increases in excess of inflation, as set forth in 42 CFR 447.509 , as updated and amended. 2. For purposes of this section, the terms "innovator multiple source

Free access — add to your briefcase to read the full text and ask questions with AI

1. Pharmaceutical manufacturers shall pay to the state, in accordance with 42 U.S.C. Section 1396r-8, rebates on eligible utilization of covered outpatient drugs dispensed to MO HealthNet participants under the MO HealthNet pharmacy program as follows:

(1) For single source drugs and innovator multiple source drugs, rebates shall reflect the manufacturer's best price, as defined by 42 CFR 447.505 , as updated and amended, and set forth in 42 CFR 447.509 , as updated and amended; and

(2) For single source drugs and innovator and noninnovator multiple source drugs, any additional rebates necessary to account for certain price increases in excess of inflation, as set forth in 42 CFR 447.509 , as updated and amended.

2. For purposes of this section, the terms "innovator multiple source drug", "noninnovator multiple source drug", and "single source drug" shall have the same meanings as defined in 42 CFR 447.502 , as updated and amended.